Topics of today

- What’s new in HBV
- How to control HBV in high endemic countries
- Imagery in liver diseases
- Vascular liver diseases
- End-stage liver disease
- Liver transplantation
- HCC
What’s new in HBV

1st Session

• Who and when to treat? Georgios Papatheodoridis
  EASL guidelines 2017

• Is there a role for interferon? Pietro Lampertico
  PEG IFN+NUC

• Long term safety and efficacy of NUCs. Maria Buti
  10 years TDF
What's new in HBV

Controversy

To stop or not to stop NUCs?

Thomas Berg and Adrian Gadano
What’s new in HBV

How to control HBV in high endemic regions

Asia  Jidong Jia
Africa Lamine Diouf
What’s new in HBV

2nd Session

• New anti-HBV therapies. Raymond Schinazi
  Future targets and combinations

• HDV co-infection. Mario Rizzetto
  Delta hepatitis revisited

• Access to therapy. Fabien Zoulim
  The next challenge
Two state of the art lectures

- The revolution of imagery in liver diseases: current management and new concepts
  Valérie Vilgrain

- Vascular liver diseases:
  Dominique Valla
End-stage liver disease and transplantation

- Infections complicating cirrhosis. Paolo Angeli

**Management in clinical practice**

- Allocation of liver grafts. Pierre-Alain Clavien

**What is the best system?**

- Long term outcome after LT. François Durand

**How to improve?**
HCC

- HCC EASL guidelines 2018. Peter Galle

  Inpress

- Impact of DAAs on HCC occurrence. Didier Samuel

  What is the best system?

- New approaches in therapy. Bruno Sangro

  New promising drugs and strategies
Take home messages
Michael Fried